The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I think Angle have until end June 2024 to publish the results for the year ended 31 December 2023. That being 6 months later. Do you concur?
I suspect there will be more news of new "household name" contracts when we get them in view of the new ones with Eisai and Astrazeneca. I will be expecting very good news.
All IMHO.
Absolutely right apologies. Now what aspect of AGL would you like to discuss???
hello everyone!
is this the right place to discuss the share price of angle plc or is it just an arena to watch grown ups ***** and argue to satisfy their own egos??
EC
Can you avoid spamming the BB with dozens of 'copy paste' posts its targer distracting and cluttering the BB...you seem to be engaged in rehashing similar earlier posts and posting multiple lengthy repeats, thanks!
This is what is going to make Angle tens if not hundreds of millions of pounds. I expect the largest Pharma Co's will want to negotiate a better rate in return for having every single one of their cancer trials involving metastasised cancer monitored by Angle. Every one. This is a ****newly available technique**** to monitor the performance of their new cancer drug ****during the drug trials****. This was previously not possible.
Think about it............ >>>
https://www.lse.co.uk/rns/AGL/breakthrough-clinical-results-b0km788ah9aflqm.html
And the presentation:-
https://www.youtube.com/watch?v=cnQ6M05BiBY
All IMHO.
Can all you ladies stop Bickering and keep on topic cheers TA
Yes indeed, not long at all. But I’d watched AGL for quite some time prior and deemed it the wrong time to invest. Whereas recently that had changed in my opinion and so far the investment I made from 11p in November and the various buys and sells I’ve made have seen me turn very significant profits and manage to increase my holding.
Sorry you chose to invest when you did and lost money.
My dear chap, you've answered my question. You have been invested a mere 6 months. Many of us have been invested for a lot longer than that old chum.
FeverTree,
I’ve been invested here since November and have been greatly encouraged by the progress made. As I’ve stated before, I don’t see this as a viable investment prior to that. Obviously you did.
Getting any business to a point where creases are ironed out and they are “match fit” in terms of moving forward toward profitability takes time. My judgement was that November was the time to buy in, whereas you, if you are invested, bought in prior at a much higher risk stage.
I agree, more contracts need to be signed and even still there still could be the need for a raise in the next 12 months as per the RNS’d cash runway forecast.
My point was that you seem deeply untrusting of the BOD, skeptical of any chance of profitability and at best you’re begrudging of the recent positive relationships with Eisai and Astra Zeneca… If I felt the same I’d have sold a long time ago and moved on. It just doesn’t make sense as to why you’re torturing yourself here.
This is what is going to make Angle tens if not hundreds of millions of pounds. I expect the largest Pharma Co's will want to negotiate a better rate in return for having every single one of their cancer trials involving metastasised cancer monitored by Angle. Every one. This is a ****newly available technique**** to monitor the performance of their new cancer drug ****during the drug trials****. This was previously not possible.
Think about it............ >>>
https://www.lse.co.uk/rns/AGL/breakthrough-clinical-results-b0km788ah9aflqm.html
All IMHO.
So, no answer to the questions I posed?
Also, they are advertising for several new staff which bodes well. I can easily imagine the sp returning to 50p plus on the back of further orders from Eisai, Astrazeneca, and numerous other World class Plc's in the next few months. Will be extremely interesting when we find out who the next massive client is!
All IMHO.
FeverTree,
Probably best you sell up then.
Tom,
How long have you been invested here? Are you aware of Newland's track record on hyping news, missing forecasts etc?
I agree that we have had positive announcements but the size of the contracts remain tiny. And I have remarked that one swallow doesn't make a summer before, and remain wary of Newland's track record that has consistently hyped news, and then disappointed. Yes, we have had 3 decent RNS deals, but none have been of any real financial consequence. Yes, Eisai & AZ are marque names, and the deals raise AGL's profile, however it's clear that institutional support for Newland/Griffiths has drained away since the the post-FDA raise at 80p, which was followed by a big revenue warning. (check FT.com). Biggest s/holder is now Global Frontiers with 6.5%, BG has 3%, Chelverton 2.8, Aegon 2%, Unicorn 1%, UN pension Fund 0.78%. Despite the positive RNS since Jan, there has been no increase in Institutional shareholders which suggests that the jury remains out on Newland. So rehabilitation of him and Griffths has a long way to go. Mean time (1) Business continues to burn cash (""m last year), and we know they need cash to plug funding gap (2) FY 23 results have still not been announced (3) Newland's on-the-record prediction of current year 3x revenues i.e £6m, looks very shaky vs revenues year to date.
See Angle's order book snowball over the next several months. I can't even imagine this not to be the case. Companies like Eisai Inc. and Astrazenica are two of the largest Pharma Companies in the World (Eisai, 49th, Astrazeneca 7th). It's "nailed on" that some of the other World leading Plc's will be placing orders with Angle. Utterly obvious. Only a fool wound think otherwise.
All IMHO.
PROBABLY HANGING ON FOR SOME GOOD NEWS TO GO WITH THE BAD
FeverTree, you’re just embarrassing yourself now.
Quick question. What frequency of positive updates (contract wins and the like) would satisfy you as a “supposed” investor? Because personally I think 2024 has been rather a productive year… Or do you not think so?
Certainly looking like we're back to familiar ploys from Newland ...'hype n hope'
So Newland & Griffiths, its 5 months since the year closed 31 December, and still no FY23 results! Not particularly reassuring for your shareholders is it
"Just shows your inexperience in trading shares. "
I'm not a Day Trader guvnor...honest lol!
Drums.
"Just looked at the fundermentals, I can't believe that not a single share has been bought today.".
------------------------------
This ridiculous comment just shows your inexperience in trading shares. Work it out for yourself. Or is this just a windup......... must be. No one is that daft!
Apologies typo H1 24.
Well as we head towards the end of H2 no sight of trebling revenues in order to extend the cash run way till Q2 2025 and I don't think tax credits count towards 'Going Concern' sign off by the Auditors and still no sight of the 2023 financial statements..not surprising really going to be another £22m loss and next stop cash placement probably at 15p....squeaky bum time for Newland!
That POLX placing will certainly not help the sector tomorrow.
Just looked at the fundermentals, I can't believe that not a single share has been bought today.